ACUMIN   Version 3.0 
 19 November,  2018  
 
 
1  
A Phase IV  Open -Label Pharmacokinetic Study of Minocycline for Injection Following a Single 
Infusion in Critically -Ill Adults (ACUMIN)  
DMID Protocol Number:  16-0011 
 
DMID Funding Mechanism:  1UM1AI104681-01 
Pharmaceutical Support Provided by:   [CONTACT_838113], Inc., a wholly owned 
subsidiary of Melinta Therapeutics Inc.  
Other Identifying Numbers:  ARLG_MINO- Yr4 
IND Sponsor:   Division of Microbiology and Infectious Diseases  (DMID)  
Principal Investigator:  [INVESTIGATOR_838097], MD 
ARLG Project Lead:   Zoë Sund  
DMID Clinical Project Manager :  Marina Lee, PhD   
DMID Medical Monitor:  Venus Shahamatdar, MD 
Version Number: 3.0 
19 November, 2018 
 
 
ACUMIN   Version 3.0 
 19 November,  2018  
 
 
2 STATEMENT OF COMPLIA NCE 
The study will be carried out in accordance with Good Clinical Practice (GCP) as required by [CONTACT_14504] (use applicable regulations depending on study location and sponsor requirements; 
samples follow) : 
• [LOCATION_002] (US) Code of Federal Regulations (CFR ) applicable to clinical studies (45  CFR 
Part 46; 21 CFR Part 50, 21 CFR Part 56, and 21 CFR Part 312) 
• ICH E6; 62 Federal Register [ZIP_CODE] (1997)  
• Clinical Terms of Award  
 
All key personnel (all individuals responsible for the design and conduct of this stud y) have 
completed Human Subjects Protection Training. 
 
ACUMIN   Version 3.0 
 19 November,  2018  
 
 
3 SIGNATURE [CONTACT_19841], and provides 
the necessary assurances that this trial will be conducted according to all stipulations o f the 
protocol, including all statements regarding confidentiality, and according to local legal and 
regulatory requirements and applicable US federal regulations and ICH guidelines. 
 
Site Investigator:  
Signed:  Date:   
 Name  
[CONTACT_838129] 3.[ADDRESS_1164132] Exclusion Criteria  ........................................................................................25  
5.3 Treatment Assignment Procedures  ...........................................................................26  
5.3.1  Randomization Procedures ...........................................................................26  
5.3.2  Masking Procedures ......................................................................................26  
5.3.3  Reasons for Study Withdrawal .....................................................................26  
5.3.4  Handling of Withdrawals from the PK Analysis ..........................................27  
5.3.5  Termination of Study ....................................................................................27  
6 Study Intervention/Investigational Product ............................................................. [ADDRESS_1164133] Description ........................................................................................28  
6.1.1  Acquisition  ....................................................................................................28  
6.1.2  Form ulation, Packaging, and Labeling .........................................................28  
[IP_ADDRESS]  Minocin IV  ........................................................................................28  
[IP_ADDRESS]  Sterile Water for Injection (WFI), USP  ............................................29  
[IP_ADDRESS]  0.9% Sodium Chloride, USP (Normal Saline) .................................[ADDRESS_1164134] Storage and Stability........................................................................29  
[IP_ADDRESS]  Minocin IV  ........................................................................................29  
[IP_ADDRESS]  Sterile Water for Injection (WFI), USP  ............................................29  
[IP_ADDRESS]  0.9% Sodium Chloride, USP (Normal Saline) .................................29  
6.2 Dosage, Preparation and Administration of Study Intervention/Investigational 
Product ......................................................................................................................29  
6.3 Modification of Study Intervention/Investigational Product for a Subject ...............30  
6.4 Accountability Procedures for the Study Intervention/Investigational Product(s) ...[ADDRESS_1164135] Compliance with Study Intervention/Investigational 
Product ......................................................................................................................30  
6.6 Concomitant Medications/Treatments  ......................................................................31  
7 Study Schedule ........................................................................................................ 32  
7.1 Screening (within 48 hours of enrollment) ...............................................................32  
7.2 Baseline (Dosing – 0 hrs) ..........................................................................................33  
7.3 1-24 hour Study Visits (post start of infusion)..........................................................33  
7.4 36 hour Study Visit (post start of infusion) ..............................................................34  
7.5 48 hour Time Point (Final Study Visit)  ....................................................................34  
7.6 SAE Follow-up Visit (as needed) .............................................................................35  
7.7 Early Termination Visit ............................................................................................35  
7.8 Unscheduled Visits ...................................................................................................35  
8 Study Procedures/Evaluations ................................................................................. 36  
8.1 Clinical Evaluations  ..................................................................................................36  
8.2 Laboratory Evaluations .............................................................................................37  
8.2.1  Clinical Laboratory Evaluations ...................................................................37  
8.2.2  Special Assays or Procedures  .......................................................................37  
8.2.3  Specimen Preparation, Handling, and Shippi[INVESTIGATOR_007] ...........................................37  
[IP_ADDRESS]  Instructions for Specimen Preparation, Handling, and Storage ........37  
[IP_ADDRESS]  Specimen Shipment ..........................................................................38  
9 Assessment of Safety  ............................................................................................... 39  
9.1 Specification of Safety Parameters  ...........................................................................39  
9.2 Methods and Timing for Assessing, Recording, and Analyzing Safety 
Parameters  .................................................................................................................39  
9.2.1  Adverse Events  .............................................................................................39  
9.2.2  Serious Adverse Events ................................................................................39  
9.2.3  Expectedness  .................................................................................................41  
9.3 Reporting Procedures ................................................................................................41  
9.3.1  Serious Adverse Events ................................................................................41  
ACUMIN   Version 3.0 
 19 November,  2018  
 
 
6 9.3.2  Regulatory Reporting for Studies Conducted Under DMID-Sponsored 
IND ...............................................................................................................42  
9.3.3  Reporting of Pregnancy ................................................................................42  
9.4 Type and Duration of Follow-up of Subjects after Serious Adverse Events ............43  
9.5 Halting Rules  ............................................................................................................43  
9.6 Safety Oversight (SMC)  ...........................................................................................43  
10 Clinical Monitoring .................................................................................................. 44  
10.1  Site Monitoring Plan  .................................................................................................44  
11 Statistical Considerations  ......................................................................................... 45  
11.1  Study Hypotheses ......................................................................................................45  
11.2  Sample Size Considerations ......................................................................................46  
11.3  Planned Interim Analyses .........................................................................................46  
11.3.1  Safety Review  ...............................................................................................46  
11.4  Final Analysis Plan  ...................................................................................................46  
11.4.1  Physiological Measures  ................................................................................46  
11.4.2  Pharmacokinetic Analysis and Assessment of Pharmacokinetic-
Pharmacodynamic Target Attainment  ..........................................................46  
12 Source Documents and Access to Source Data/Documents  .................................... 48  
13 Quality Control and Quality Assurance ................................................................... 49  
14 Ethics/Protection of Human Subjects ...................................................................... [ADDRESS_1164136]  .......................................................................................50  
14.3  Informed Consent Process ........................................................................................50  
14.4  Exclusion of Women, Minorities, and Children (Special Populations) ....................[ADDRESS_1164137] Keepi[INVESTIGATOR_007]  ........................................................................ 52  
15.1  Data Management Responsibilities ...........................................................................52  
15.2  Data Capture Methods  ..............................................................................................52  
15.3  Types of Data  ............................................................................................................52  
15.4  Timing/Reports  .........................................................................................................53  
15.5  Study Records Retention ...........................................................................................53  
15.6  Protocol Deviations ...................................................................................................53  
16 Publication Policy  .................................................................................................... 54  
17 Literature References  ............................................................................................... 55  
Supplements/Appendices  .............................................................................................................. 56  
Appendix A: Schedule of Events .................................................................................................. [ADDRESS_1164138] OF TABLES  
Table 1: Schedule of Events ......................................................................................................... [ADDRESS_1164139] OF FIGURES  
Figure 1: ACUMIN Study Diagram  ............................................................................................. 14  
Figure 2: Structural Formula of Minocin IV................................................................................. [ADDRESS_1164140] quantifiable sample after a dose  
AUC 0-∞ Area under the plasma drug concentration -time curve from 0 to infinity 
after a dose  
BLQ  Below Limit of Quantita tion 
BPM  Beats per minute  
BUN  Blood urea nitrogen 
CFR  Code of Federal Regulations  
CI Confidence interval  
CL Clearance  
CLd Distribution clearance  
Cmax  Maximum plasma  drug concentration 
C24 Plasma drug concentration at 24-hours after a dose 
CROMS  Clinical Research Operational Management Support  
DHHS  Department of Health and Human Services  
DMID  Division of Microbiology and Infectious Diseases, NIAID, NIH, DHHS 
eCRF  Electronic Case Report Form  
ACUMIN   Version 3.0 
 19 November,  2018  
 
 
10 fAUC:MIC  Free-drug AUC:MIC ratio  
FDA  Food and Drug Administration  
FOCEI  First-order conditional estimation method with interaction  
FWA  Federalwide Assurance  
GCP  Good Clinical Practice  
hCG Human Chorionic Gonadotropin 
HCl Hydrogen chloride 
ICF Informed Consent Form 
ICH International Council for Harmonization  
ICMJE  International Committee of Medical Journal Editors 
ICU Intensive Care Unit  
IDES  Internet Data Entry System 
IH Intrac ranial hypertension 
IND Investigational New Drug Application  
IRB Institutional Review Board  
IV Intravenous 
LAR  Legally Authorized Representative 
LCE  Leukocyte esterase  
LC-MS Liquid chromatography assay with mass spectrophotometry detection 
LLOQ  Lower Limit of Quantification  
MDR  Multiple Drug Resistant  
MIC  Minimum Inhibitory Concentration  
mg Milligrams  
mL Milliliters  
MOP  Manual of Procedures 
NCA Non-compartmental analysis  
NDA  New Drug Application  
ACUMIN   Version 3.[ADDRESS_1164141] error of the mean  
SMC  Safety Monitoring Committee  
SSR Safety Summary Report  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction  
TEAE Treatment -Emergent Adverse Events  
Tmax Time at which the maximum plasma drug concentration occurs 
US [LOCATION_002]  
USP [LOCATION_002] Pharmacopeia  
Vc Volume of distribution in central compartment  
Vp Volume of distribution in the peripheral compartment 
Vss Volume of distribution at  steady state  
WBC  White blood cell count 
WFI Water for injection  
 
 
ACUMIN   Version 3.0 
 19 November,  2018  
 
 
12 PROTOCOL SUMMARY  
Title:  A Phase IV  Open -Label Pharmacokinetic Study of 
Minocycline for Injection Following a Single Infusion in 
Critically -Ill Adults (ACUMIN)  
Phase:  Phase IV 
Population: Up to 67 subjects enrolled to obtain 50 evaluable,  critically -ill 
adults with illness known or suspected to be caused by 
[CONTACT_838114] -negative bacteria  
Number of Sites:  Approximately 13 clinical sites  
Study Duration:  Approximately [ADDRESS_1164142] Participation Duration: Approximately 2 days  
Description of Agent or 
Intervention:  Minocin® IV (minocycline hydrochloride injection) 200mg administered intravenously as a single infusion over 
approximately 60 minutes  
Objectives : 
 Primary:  
To characterize minocycline PK at the population level in 
critically -ill adults, with illness known or suspected to be 
caused by [CONTACT_838114] -negative bacteria  
To assess patient -level and clinical covariates associated with 
minocycline pharmacokinetic properties in critically -ill adults , 
with illness known or suspected to be caused by [CONTACT_838114] -negative bacteria  
 
Exploratory:  
To predict the distribution of concentration- time profiles 
observed with the FDA approved minocycline dosing regimen in critically -ill adults, with illne ss known or suspected to be 
caused by [CONTACT_838114] -negative bacteria via 
simulations  
ACUMIN   Version 3.[ADDRESS_1164143] strains 
To evaluate changes of physiological parameters following a 
single infusion of minocycline among criticall y-ill adults.  
Description of Study 
Design:  Unblinded, single-dose, population PK study  
Estimated Time to 
Complete Enrollment:  Approximately 16 months 
ACUMIN                  Version 3.0  
   19 November, 2018  
 
 
14 Figure 1: ACUMIN Study Diagram  
  

ACUMIN   Version 3.0 
 19 November, 2018  
 
 
15 1 KEY ROLES  
Individuals:  
 
   
 
   
 
 Principal Investigator  
[CONTACT_24617] G. Wunderink, MD 
Medical Director, Medical Intensive Care Unit  
Northwestern University of Feinberg School of Medicine [ADDRESS_1164144] Huron,  
McGaw M -336 
Chicago, IL [LOCATION_003] [ZIP_CODE] 
Phone: [PHONE_17457] 
Email: [EMAIL_15902]  
 Co-Investigator 
Thomas Lodise, PharmD, PhD 
Professor, Pharmacy Practice  
Albany College of Pharmacy and Health Sciences  
Albany, [LOCATION_001] NY [ZIP_CODE] -3492 
Phone:  [PHONE_17458] 
Email: [EMAIL_15903]   ARLG Project Leader  
Zoë Sund 
[ADDRESS_1164145] 
Durham, NC [ZIP_CODE] Phone:  [PHONE_17459] Email:  [EMAIL_15904] 
  DMID Clinical Protocol Manager   
Marina Lee, PhD  
[ADDRESS_1164146], 7E17 
Rockville MD [ZIP_CODE] 
Phone: [PHONE_17460] 
Email: [EMAIL_15905]  
  
 
ACUMIN   Version 3.[ADDRESS_1164147], Room 7E54, MSC 9826 
Bethesda, MD [ZIP_CODE]  
Phone: [PHONE_17461] Email: [EMAIL_13880]  
 
Melinta Therapeutics : Paula M. Bokesch, MD, FAAP Medical Director  
Melinta Therapeutics, Inc. 
[ADDRESS_1164148] 
Morris town, NJ [ZIP_CODE] Phone:  
Email:  [EMAIL_15906] 
 
Safety and Pharmacovigilance 
Contractor:  
 Clinical Research Operations and Management Support 
(CROMS)  
[ADDRESS_1164149]., Suite 650  Bethesda, MD [ZIP_CODE]  SAE Hot Line: 1 -[PHONE_889] (US)  
SAE Fax: [PHONE_2620] (US)  
SAE Email: [EMAIL_1393]  
 
Statistical and Data 
Coordinating Center:  
 The Emmes Corporation 
[ADDRESS_1164150]., Suite 700 
Rockville, MD [ZIP_CODE] Phone: [PHONE_17462]  Email: [EMAIL_13881]  
 

ACUMIN   Version 3.0 
 19 November, 2018  
 
 
17 Study Agent Repository:  
 Fisher BioServices  
c/o DMID Clinical Materials Services  Contract  
[ADDRESS_1164151]  
Germantown, MD [ZIP_CODE]  
Phone: [PHONE_17463] Fax: [PHONE_17464]  
Email: DMID. CMS @ThermoFisher.com  
  
PK Laboratory : Syneos Health  
2500, rue Einstein 
Québec, Canada G1P 0A2  
Phone:   
Email: marieeve.coulombe@ syneos health.com  
 
 
 

ACUMIN   Version 3.[ADDRESS_1164152] approved in the [LOCATION_002] (US) as both oral and 
intravenous (IV) formulations in the 1970s. The original IV formulation of minocycline was 
approved in the US on 26 October 1972. Rempex Pharmaceuticals, Inc., a wholly owned subsidiary of Melinta Therapeutics , Inc., has developed a new formulation, Minocin
® 
(minocycline) for Injection (referred to as Minocin IV in this protocol), which was approved by [CONTACT_3133] (FDA) on 17 April, 2015 (NDA 50,444). The new formulation is comprised of minocycline hydrochloride with magnesium sulfate to improve the solubility and stability of minocycline solutions at a more physiological pH, which enables 
administration of minocycline in a smaller volume of fluid. The approved indication for Minocin 
IV includes the treatment of infections due to susceptible strains of several important Gram-positive and Gram-negative pathogens, including Acinetobacter  species.  Minocycline has 
excellent in vitro  microbiologic activity against multi-drug resistant Acinetobacter baumannii  
species ,
1-3 a gro wing world -wide problem.4-9 Furthermore, IV minocycline has been in use for 
over four decades and has a well -established safety profile.  
2.2 Rationale  
This study will examine the pharmacokinetics (PK) of Minocin IV in critically -ill patients with 
Gram -negative infections in the Intensive Care Unit (ICU).  Whil e there is longstanding clinical 
use experience with minocycline in patients, PK studies of minocycline are relatively limited and were conducted in the 1970s in healthy volunteers. Pharmacokinetic data from a single study in 10 healthy male subjects is reported in the USPI [INVESTIGATOR_838098] a single dose of 
Minocin IV 200 mg, serum concentrations of minocycline ranged from 2.52 μg/mL to 6.63 
μg/mL (average of 4.18 μg/mL) at the end of infusion and 0.82 μg/mL to 2.64 μg/mL (average of 1.38 mcg/mL) after 12 hours.  The label further states that following administration of Minocin IV 100 mg administered every 12 hours for three days to five healthy male subjects, serum 
concentrations of minocycline ranged from 1.4 μg/mL to 1.8 μg/mL at the end of the dosing 
interval.
[ADDRESS_1164153] been observed in patients receiving any tetracyclines and 
are included in the Minocin® (minocycline) for Injection Package Insert.  
Body as a whole:  Fever and discoloration of secretions. 
Gastrointestinal: Anorexia, nausea, vomiting, diarrhea, dyspepsia, stomatitis, glossit is, 
dysphagia, enamel hypoplasia, enterocolitis, pseudomembranous colitis, pancreatitis, and 
inflammatory lesions (with monilial overgrowth) in the oral and anogenital regions. These reactions have been caused by [CONTACT_838115].   
Genitourinary: Vulvovaginitis. 
Hepatic toxicity: Hyperbilirubinemia, hepatic cholestasis, increases in liver enzymes, fatal  
hepatic failure, and jaundice. Hepatitis, including autoimmune hepatitis and liver failure, has been reported.  
Skin: Alopecia, erythema nodosum, hyperpi[INVESTIGATOR_447137], pruritus, toxic epi[INVESTIGATOR_838099], and maculopapular and erythematous rashes. Exfoliative dermatitis has been reported. Fixed drug eruptions have been reported. Lesions occurring on the glans penis 
have caused balanitis. Erythema multiforme and Stevens-Johnson syndrome have been reported.  
Photosensitivity and pi[INVESTIGATOR_838100].  
Local reactions:  Injection site erythema and injection  site pain.  
Respi[INVESTIGATOR_696]:  Cough, dyspnea, bronchospasm, exacerbation of asthma, and pneumonitis. 
Renal toxicity: Interstitial nephritis. Elevations in blood urea nitrogen (BUN) have been reported 
and are apparently dose- related.  Acute renal failure has been reported.  
Musculoskeletal:  Arthralgia, arthritis, bone discoloration, myalgia, joint stiffness, and joint 
swelling.  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
20 Hypersensitivity reactions: Urticaria, angioneurotic edema, polyarthralgia,  
anaphylaxis/anaphylactoid reaction (including shock and fatalities), anaphylactoid purpura, 
myocarditis, pericarditis, exacerbation of systemic lupus erythematosus, and pulmonary 
infiltrates with eosinophilia have been reported. A lupus-like syndrome and serum sickness- like 
reactions have also been reported.  
Blood: Agranulocytosis, hemolytic anemia, thrombocytopenia, leukopenia, neutropenia, 
pancytopenia, and eosinophilia have been reported. 
Central nervous system: Convulsions, dizziness, hypoesthesia, paresthesia, sedation, and vertigo.  
Pseudotumor cerebri (benign intracranial hypertension [IH]) in adults and bulging fontanels in 
infants have been reported.  Headache has also been reported.  
Other:   Thyroid cancer has been reported in the post marketing  setting in association with 
minocycline products.  When min ocycline therapy is given over prolonged periods, monitoring  for signs 
of thyroid cancer should be considered.  When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of the thyroid gland.  Cases of 
abnormal thyroid function have been reported. 
Tooth discoloration in pediatric patients less than eight years of age and in adults has been 
reported. 
Oral cavity discoloration (including tongue, lip, and gum) has been reported.  Tinnitus and 
decreased  hearing have been reported.  
The following syndromes have been reported; in some cases involving these syndromes, death has been reported.  As with other serious adverse reactions, if any of these syndromes are 
recognized, the drug should be discontinued i mmediately:  
Hypersensitivity syndrome consisting of cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, and one or more of the following: hepatitis, pneumonitis, nephritis, 
myocarditis, and pericarditis.  Fever and lymphadenopathy ma y be present.  
Lupus- like syndrome consisting of positive antinuclear antibody; arthralgia, arthritis, joint 
stiffness, or joint swelling; and one or more of the following: fever, myalgia, hepatitis, rash, and 
vasculitis.  
Serum sickness -like syndrome consisting of fever, urticarial, or rash; and arthralgia, arthritis, 
joint stiffness, or joint swelling.  Eosinophilia may be present. 
Minocin IV contains subtherapeutic levels of magnesium sulfate heptahydrate. Adverse effects that may be associated with magnesium intoxication include flushing, sweating, hypotension, 
depressed reflexes, flaccid paralysis, hypothermia, circulatory collapse, cardiac and central 
nervous system depression proceeding to respi[INVESTIGATOR_4939]. 
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
21 2.3.2 Known Potential Benefits  
This is a non- treatment study and subjects are not expected to benefit by [CONTACT_838116].  The study will provide critical PK and PK/PD data in an ICU patient population where 
Minocin IV is likely to be used for the treatment o f Acinetobacter  infections.  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
22 3 OBJECTIVES  
3.1 Study Objectives  
Primary objectives: 
To characterize minocycline PK  at the population level in critically -ill adults, with illness known 
or suspected to be caused by [CONTACT_838114]- negative bacteria. 
To assess patient -level and clinical covariates associated with minocycline pharmacokinetic 
properties in critically -ill adults, with illness known or suspected to be caused by [CONTACT_838117] -negative bacteria.  
Exploratory objectives: To predict the distribution of concentration-time profiles observed with the FDA approved 
minocycline dosing regimen in critically -ill adults, with illness known or suspected to be caused 
by [CONTACT_838114]- negative bacteria via simulations . 
To assess whether  dosing adjustments for the approved FDA minocycline dosing regimen are 
needed based on identifiable patient- level and clinical covariates among critically -ill adults, with 
illness known or suspected to be caused by [CONTACT_838114]- negative bacteria via 
simula tions.  
Conduct simulation studies to determine the ability of the FDA approved minocycline dosing 
scheme to achieve critical pharmacokinetic -pharmacodynamic  targets against the range of 
minocycline MIC values observed with infections due to Acinetobacter baumannii, including 
MDR strains. 
To evaluate changes of physiological parameters following a single infusion of minocycline 
among critically -ill adults.  
 
3.2 Study Outcome Measures  
3.2.1 Primary Outcome Measures  
Population mean PK parameter estimates and the magnitude of the associated inter -individual 
variability for free -drug and total-drug clearance (CL), central volume of distribution (Vc), 
distribution clearance (CLd), and the peripheral volume of distribution (Vp), determined using nonlinear mixed effects mode ling on PK time points collected up to [ADDRESS_1164154]- hoc PK parameter estimates and calculated exposure measures after a single dose 
such as the maximum plasma concentration (C max), the plasma concentration at 24 hours after a 
dose (C 24), the area under the curve from 0 to 24 hours after a dose (AUC 0-24), the area under the 
curve to the last quantifiable sample (AUC 0-last), and area under the curve from 0 to infinity 
(AUC 0-inf) using both free-drug and total- drug c oncentrations. 
3.2.2 Exploratory Outcome Measures  
Distribution of simulated concentration -time profiles with the FDA approved minocycline dosing 
regimen across the patient -level and clinical covariates patterns in the final population PK model.   
Comparison of the observed simulated concentration- time profiles in critically -ill adults, with 
illness known or suspected to be caused by [CONTACT_838114]- negative bacteria with simulated 
concentration -time profiles in healthy adults.   If needed, dose adjustment calculations will be 
made.  
Probability of achieving free- drug AUC:MIC ratio ( fAUC:MIC) ≥ 12 (PK- PD target for bacterial 
stasis), and probability of achieving f AUC:MIC  ratio ≥ 18 (PK- PD target for 1 -log 10 CFU kill), 
for FDA -approved minocycline dosing regimens. 
Change from baseline at 48hr post-dose in :  
liver function tests  
magnesium  
serum creatinine  
ACUMIN   Version 3.[ADDRESS_1164155] 7 PK samples collected ([ADDRESS_1164156]-dose) at de signated 
time points over a ~[ADDRESS_1164157] (1) have the baseline pre- dose PK sample collected (2) 
receive the full infusion of study drug, (3) have at least [ADDRESS_1164158] dose, (4) have at least [ADDRESS_1164159] dose, and (5) PK 
specimens processed per the Manual of Procedures.  
For subjects who receive the full infusion of study drug but are not PK evaluable, their available PK data may still be used in the final PK analyses i f certain criteria listed in the Statistical 
Analysis Plan are met.  
 
  
 
  
ACUMIN   Version 3.[ADDRESS_1164160] meet all of the following criteria in order to be eligible for the study:  
1. Male or female ≥[ADDRESS_1164161] , or legal ly authorized representative (LAR) , is able and willing to provide 
signed informed consent 
5.[ADDRESS_1164162] Exclusion Criteria 
Subjects who meet any of the following criteria at baseline will not be enrolled in the study:  
1. History of significant hypersensitivity or allergic reaction to tetracycline antibiotics  
2. Receipt of oral or intravenous tetracycline class drugs within 7 days of enrollment (e.g., 
minocycline, tetracycline, tigecycline, doxycycline)  
3. Use of isotretinoin within [ADDRESS_1164163] been used in the 
previous 30 days 
  
1 Major surgery is defined as “the opening of either a body cavity or the mesenchymal barrier, using general 
anesthesia”  
2 Subjects on, or who may be considered for Renal Replacement Therapy (RRT) during the study period are not 
excluded from participating in the study . 
 
5.3 Treatment Assignment Procedures  
5.3.1 Randomization Procedures  
This is a single arm study. There are no randomization procedures.  Subjects will be enrolled 
online through the enrollment module of AdvantagEDCSM, the Emmes Corporation’s Internet 
Data Entry System (IDES).  Instructions for use of the enrollment module are included in the AdvantagEDC
SM User’s Guide.  Manual back-up enrollment procedures are provided in the 
MOP for use in the event that the site temporarily loses access to the internet or the online 
enrollment system is unavailable.  
5.3.[ADDRESS_1164164] may withdraw or be withdrawn from this study for any of the following reasons: 
• Medical disease or condition, or any new clinical findings for which continued 
participation, in th e opi[INVESTIGATOR_29352]-
investigator, would compromise the safety of the subject, or would interfere with the 
subject's successful completion of the study, or would interfere with the evaluation of responses. 
• As deemed necessary by [CONTACT_16541] [INVESTIGATOR_29353]- investigator for 
noncompliance or other reasons. 
• Subject withdrew consent.  
ACUMIN   Version 3.[ADDRESS_1164165]’s Minocin infusion at any time if medically 
necessary.  The reaso n(s) for early discontinuation should be reflected in the source 
documentation and on the appropriate eCRF.   
5.3.[ADDRESS_1164166] . 
5.3.5 Termination of Study  
The DMI D/NIAID, ARLG, FDA and/or Rempex Pharmaceuticals, Inc. /Melinta Therapeutics 
Inc. have the right to discontinue this study at any time for medical and/or administrative 
reasons.  For subjects  who received minocycline prior to the termination of the study, all safety 
related procedures described  in this protocol should be performed.   
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
28 6 STUDY INTERVENTION/I NVESTIGATIONAL 
PRODUCT 
6.[ADDRESS_1164167] Description  
Minocin IV is a sterile formulation of a semisynthetic derivative of tetracycline. The chemical 
name [CONTACT_4007] m inocycline is 4,7- Bis(dimethylamino) -1,4,4a,5,5a,6,11,12a- octahydro -3,10,12,12a- 
tetrahydroxy -1,11-dioxo-2-naphthacenecarboxamide monohydrochloride. 
Its structural formula is:  
Figure 2: Structural Formula of Minocin IV  
 
C23H27N3O7•HCl M.W. 493.94 
6.1.1 Acquisition  
Minocin IV will be supplied by [CONTACT_838113], Inc., a wholly owned subsidiary of Melinta Therapeutics, Inc.    
Sterile water for injection, USP and 0.9% Sodium Chloride, USP (normal saline) will be 
supplied by [CONTACT_133032] . 
Study product will be shipped to the investigational site upon request and approval by [CONTACT_122830]. 
6.1.2 Formulation, Packaging, and Labeling 
[IP_ADDRESS] Minocin IV  
Minocin IV is supplied as a sterile yellow to amber lyophilized powder for intravenous infusion 
in a single -use 10 mL glass vial with a rubber stopper and aluminum overseal. Each vial 
contains108 mg of minocycline hydrochloride (equivalent to 100 mg of minocycline) , 269 mg 
magnesium sulfate heptahydrate (2.2 mEq of magnesium) (an inactive ingredient) and sodium hydroxide (to adjust pH). When reconstituted with 5 mL of Sterile Water for Injection USP the pH ranges from 4.5 to 6.0.  Further information can be found in the Manual of Procedures  and 
Minocin
® (minocycline) for Injection Package Insert.  

ACUMIN   Version 3.0 
 19 November, 2018  
 
 
29 [IP_ADDRESS] Sterile Water for Injection  (WFI) , USP  
The sterile water for injection (WFI), USP is nonpyrogenic and contains no bacteriostatic, 
antimicrobial agent, or added buffer.  This product should be used to reconstitute the Minocin IV vial.  WFI will be obtained as a single -dose container.   
[IP_ADDRESS] 0.9% Sodium Chloride, USP (Normal Saline)  
0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection.  Each mL contains 9 mg of sodium chloride and contains no 
preservatives, bacteriostatic, antimicrobial agent, or added buffer.  The solution is clear in 
appearance and may contain hydrochloric acid and/or sodium hydroxide for pH adjustment (pH 
5.3 [4.5 to 7.0]).  Normal saline will be obtained in [ADDRESS_1164168] Storage and Stability  
[IP_ADDRESS] Minocin IV  
Vials containing lyophilized Minocin IV are stored at controlled room temperature of 20°C to 25°C (68°F to 77°F). Per the USP controlled room tempe rature requirement, excursions between 
15°C and 30°C (59°F and 86°F) are permitted . Once reconstituted, Minocin IV bags can be 
stored at room temperature for up to 4 hours or refrigerated at 2°C to 8°C (36°F to 46°F) for up 
to 24 hours.  Further details can be found in the Manual of Procedures and Minocin
® 
(minocycline) for Injection Package Insert.  
[IP_ADDRESS] Sterile Water for Injection  (WFI) , USP  
The sterile WFI vials are stored at 20ºC to 25ºC (68°F to 77ºF) [See USP Controlled Room 
Temperature; excursions between 15°C and 30°C (59°F and 86°F) are permitted].  
[IP_ADDRESS] 0.9% Sodium Chloride, USP (Normal Saline)  
Store at 20ºC to 25ºC (68°F to 77ºF) [See USP Controlled Room Temperature; excursions 
between 15°C and 30°C (59°F and 86°F) are permitted].  Protect from freezing. 
6.2 Dosage, Preparat ion and Administration of Study 
Intervention/Investigational Product  
Two-100 mg vials of Minocin IV are required for each single dose.  The lyophilized powder in 
each vial (approximately 108 mg/vial, equivalent to 100 mg upon reconstitution) should be 
reconstituted  with 5  mL of Sterile Water for Injection (10mL total).  10 mL should be removed 
from the 100 mL bag of Sodium Chloride Injection, USP.  The contents of the two reconstituted vials of Minocin IV should be transferred aseptically to the bag of Sodium Chloride Injection 
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
30 USP, and then mixed by [CONTACT_8536]. Once diluted into an intravenous bag, the infusion may be 
stored at room temperature  (20° to 25°C) and administered within  4 hours, or refrigerated at 2 to 
8°C (36 to 46°F) and administer ed within 24 hours of preparation.  
Subjects will receive a single 200 mg intravenous infusion of Minocin IV in 100 mL of normal 
saline  administered at  a rate of 100  mL/ hour and until the bag is empty and the line is flushed .  
Additional study product preparation details are further described in the protocol- specific 
Manual of Procedures.   
6.3 Modification of Study Intervention/Investigational Product for a 
Subject  
This is a single dose study. There will be no dose modifications pe rmitted.    
6.4 Accountability Procedures for the Study Intervention/Investigational 
Product(s)  
The site principal investigator [INVESTIGATOR_838101], 
and has ultimate responsibility for accountability.  The site principal investigator [INVESTIGATOR_838102].  If delegated, the site Research Pharmacist 
will be responsible for maintaining complete records and documentation of study product receipt, accountability, dispensation, temperature monitoring, and storage conditions, and final 
disposition of the study product.   
All study products, whether administered or not, must be documented on the appropriate study 
product accountability record or dispensing log.  Used and unused Minocin IV vials will be retained until monitored and then released for disposition.  Any unused solution left in the IV 
infusion bag or IV administration tubing after administration to the subject should be discarded 
as biohazardous waste.  
Upon completion of the study and after the final monitoring visit, any remaining unused study 
product will either be returned or destroyed appropriately at the clinical site as per sponsor 
requirements and instructions, or in accordance with disposition plans. 
6.[ADDRESS_1164169] Compliance with Study 
Intervention/Investigational Product  
Study drug compliance including start and stop time of infusion, volume administered, and the occurrence of any infusion interruptions (greater than 10 minutes) will be captured in the source documents. 
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
31 6.6 Concomitant Medications/Treatments  
In this study, a single dose of Minocin IV is being administered, and as such, is unlikely to result 
in significant medication interaction.  However, the following are listed in the Minocin® 
(minocycline) for Injection Package Insert as precautions or warnings:  
Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are 
on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.  
Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable 
to avoid giving tetracyclines in conjunction with penicillin.  
The concurrent use of tetracyclines and methoxyflurane has been reported to result in fatal renal 
toxicity.  
Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.  
Administration of isotretinoin should be avoided shortly before, during, and shortly after minocycline therapy. Each drug alone has been associated with pseudotumor cerebri.  
Increased risk of ergotism when ergot alkaloids or their derivatives are given with tetracyclines.  
Minocin IV contains magnesium sulfate heptahydrate. Potentially serious drug interactions may 
occur when intravenous magnesium sulfate heptahydrate is given concomitantly with CNS 
depressants, neuromuscular blocking agents and cardiac glycosides. 
Concomitant and treatment medications  will be collected  from [ADDRESS_1164170] start of  infusion (total of 72 hours) , as well as  the SAE follow-up 
visit as needed . 
Receipt of any renal replacement therapi[INVESTIGATOR_014]  (RRT)  will be collected from [ADDRESS_1164171] start of infusion. 
  
  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
32 7 STUDY SCHEDULE  
The foll owing sections describe the study procedures and data collected. For each procedure, 
subjects are to be assessed by [CONTACT_838118]. A Schedule of Ev ents is located 
in Appendix A . 
7.1 Screening (within 48 hours of enrollment ) 
Informed consent must be obtained prior to the subject entering into the study, and before any 
protocol- directed procedures are performed.  Subjects will be screened in accordance with 
predefined inclusion and exclusion criteria as described in Section 5. 
Subjects /LAR s will be provided with a description of the study (purpose and study procedures) 
and asked to read and sign the informed consent form. After the subject has provided informed consent to participate in the study, screening will include: 
Review eligibility criteria with the subject and/or LAR  
Complete medical history 
 
Demographic  information (age, gender, race, ethnicity)   
Height  (can  be pulled from medical records associated with the current hospi[INVESTIGATOR_838103]) 
Targeted physical examination  
Vital signs  
Collect concomitant medications (starting  24 hours prior to start of infusion) 
Clinical laboratory evaluations to include (see Section 8.2.[ADDRESS_1164172] of tests) *: 
Blood c hemistry  
Serum creatinine (if not included in clinical chemistry)  
Liver function te sts 
Hematology  
Magnesium  
Urinalysis  
Serum hCG pregnancy test, from women of childbearing potential 
* Standard of care results obtained for clinical care purposes within 48hrs of screening are acceptable for screening. 
A pregnancy test at any time during the current hospi[INVESTIGATOR_838104].  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
33 7.2 Baseline  (Dosing – 0 hrs ) 
If the subject has satisfied all of the inclusion criteria and none of the exclusion criteria, the 
subject should be enrolled as described in Section 5.3. The following procedures will be 
completed:  
Blood c hemistry (if not collecte d within 8 hours prior to  the start of study drug infusion) 
Liver function tests (if not collecte d within 8 hours prior to the start of study drug infusion) 
Hematology (if not collecte d within 8 hours prior to the start of study drug infusion) 
Vital signs, collected as close to the start of the study drug infusion as possible 
Weight, collected as close to the start of the study drug infusion as possible 
PK blood samples, collected just prior to  the start of  study drug infusion 
Serum creatinine , collected just prior to  the start of study drug infusion 
Magnesium , collected just prior to  the start of study drug in fusion 
Administration of a single dose of Minocin IV in the ICU under the supervision of the investigator or designee  
Collection of concomitant medications, including IV medications administered during the time 
of Minocin infusion (refer to the Manual of Procedures for details)  
Serious a dverse event collection (SAEs will be collected from the start of the investigational 
drug infusion and will continue for 24 hours from that point.) 
7.3 1-24 hour  Study Visits (post start of infusion)  
Vital signs collected at 1  hour and at 24 hours  
Weight  collected at 24  hour s 
Collection of concomitant medications, including IV medications administered (refer to the 
Manual of Procedures for details) 
Collection of any RRTs being received  
Serious a dverse event collection  (SAEs will be collected from the start of the investigational 
drug infusion and will continue for 24 hours from that point.)  PK blood samples collected at the following time points: Immediately after the end of infusion (1 
hour), 4 hours, 12 hours and 24 hours  
Serum creatinine collected at the following time points: Immediately after the end of infusion (1 
hour), 4 hours, 12 hours and 24 hour s 
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
34 Magnesium collected at 24 h ours  
Hematology at 24 hours  
NOTE:  Study time point windows are detailed in the S chedule of Events ( Appendix A ) 
7.4 36 hour  Study Visit (post start of infusion)  
Subjects will undergo the following procedures:  
Collection of concomitant medications, including IV medications administered (refer to the 
Manual of Procedures for details) 
PK blood samples collected at 36 hours 
Serum creatinine collected at 36 hours Collection of any RRTs being received  
Follow-up on any reported SAEs NOTE:  Study time point windows are  detailed in the S chedule of Events  (Appendix A ) 
7.5 48 hour Time Point (Final Study Visit ) 
The final study visit will occur at 48 hours after the start of infusion. Subjects will undergo the 
following procedures:  Vital signs collected at 48 hours  Hematology at 48 hours  
Weight  
Collection of concomitant medications, including IV medications (refer to the Manual of 
Procedures for details)  
Collection of any RRTs being received  
Follow-up on any reported SAEs 
PK blood samples collected at 48 hours Clinic al laboratory evaluations to include:  
Liver function tests Serum creatinine  
Magnesium  
NOTE:  Study time point windows are  detailed in the S chedule of Events ( Appendix A ) 
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
35 7.6 SAE Follow -up Visit  (as needed)  
Targeted physical examination  
Vital signs  
Collect concomitant medications  
Clinical laboratory evaluations , as needed   
Follow-up on any SAEs  
7.[ADDRESS_1164173] be documented in the source 
document and e CRF.  If at all possible, vital signs and laboratory tests obtained for clinical 
purposes should be recorded at early termination.  
7.8 Unscheduled Visit s  
Unscheduled visits will occur at the investigators discretion.  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
36 8 STUDY PROCEDURES/EVALUATIONS  
8.[ADDRESS_1164174] (IRB). Any protocol deviations 
will be documented.  
Complete medical history will be obtained by [CONTACT_838119]’s LAR during 
screening.  Subject will be queried regarding a history of significant medical disorders and any 
allergies.   
RRT data will be collected for subjects who undergo RRT, starting one hour  from the start of 
the minocycline infusion through [ADDRESS_1164175] infusion, per the Manual of Procedures. 
Medications  history (concomitant medications) will include a review of all medications  taken 
within [ADDRESS_1164176] infusion, as well as the SAE 
follow-up visit as needed. Pertinent data for concomitant medications will be documented  per the 
Manual of Procedures. Per the exclusion crit eria, the following medications will also be 
documented: 
Isotretinoin within [ADDRESS_1164177] within 7 days prior to enrollment 
A targeted physical examination  and examination of specific systems to be guided by 
[CONTACT_838120], will be performed during screening , as well as the SAE follow -up as needed .  
All physical examinations will be performed by a study clinician licensed to make medical 
diagnoses.  
Vital signs, including systolic and diastolic blood pressures (mm Hg), heart rate (HR) ,   
respi[INVESTIGATOR_697], and temperature will be recorded  at the indicated time points.  Please refer to the 
Manual of Procedures for details. 
Height  and weight will be measured  or calculated per the Manual of Procedures, rather than 
estimated or by [CONTACT_838121].   
ACUMIN   Version 3.[ADDRESS_1164178] with the new ranges and effective dates.  The normal laboratory reference ranges 
will also be retained in the Regulatory Binder at each site. Laborato ry tests will be obtained from 
screening through the final study visit (48 hours). Refer to the Schedule of Events located in 
Appendix A . The laboratory tests to be performed are listed below.  
Hematology - hemoglobin, hematocrit, white blood cell count (WBC) , WBC differential, red 
blood cell count, platelets 
Clinical chemistry  - potassium, sodium, chloride, bicarbonate, glucose, blood urea nitrogen, 
serum creatinine  
Liver function tests:  AST, ALT, alkaline phosphatase, albumin, total bilirubin  
Magnesium  
Serum hCG pregnancy test (females of child bearing potential only)   
Urinalysis - protein, glucose, ketones, bilirubin, blood, nitrites, LCE, urobilinogen, specific 
gravity,  and pH  
8.2.2 Special Assays or Procedures  
Pharmacokinetic blood samples will be collected  at the appropriate time points.  Plasma will be 
separated and stored frozen, preferably  at -80°C; however, use of a -20°C freezer  prior to 
shippi[INVESTIGATOR_838105] 2 weeks.  Plasma PK samples will be 
analyzed for both free and total minocycline concentrations in plasma using a validated liquid 
chromatography assay with mass spectrophotometry detection (LC- MS). Please refer to the 
Manual of Procedures for more complete details.  
8.2.3 Specimen Preparation, Handling, and Shippi[INVESTIGATOR_007]  
[IP_ADDRESS] Instructions for Specimen Preparation, Handling, and Storage  
Specimen preparation, handling and storage instructions are included in the Manual of Procedures . 
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
38 [IP_ADDRESS] Specimen Shipment  
Specimen shipment instructions are included in the Manual of Procedures.  
ACUMIN   Version 3.[ADDRESS_1164179] multiple events  due to their underlying disease, only SAEs will be captured in this 
protocol.   
9.2.2 Serious Adverse Events  
An adverse event is considered “serious” if, in the view of either the investigator or sponsor, it 
results in any of the following outcomes:  
Death,  
A life -threatening adverse event,[ADDRESS_1164180] normal 
life functions, or  
A congenital anomaly/birth defect.   
Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_12190], based upon appropriate medical judgment they 
may jeopardize the subject and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition.  Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias 
                                                 
 
2 Life-threatening adverse event. An adverse event is considered “life- threatening” if, in the view of either the 
investigator or sponsor, its occurrence places the patient or subject at immediate risk of death.  It does not include an 
adverse event, had it occurred in a more severe form,  that might have caused death. 
 

ACUMIN   Version 3.0 
 19 November, 2018  
 
 
40 or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug 
dependency or drug abuse. 
All SAEs will be:  
recorded on the app ropriate SAE eCRF  
followed through resolution by a study clinician reviewed and evaluated by a study clinician  
SAEs will be collected from the start of the investigational drug infusion and will continue for 24 
hours from that point. As the study population in this protocol are critically ill patients, the utility 
of SAE collection (i.e., the ratio between true safety signal and all events that meet the SAE criteria), might be low. The study team will evaluate the utility of SAE collection on a regular 
basis and will consider change in duration, scope or intensity of SAE collection. Any changes in 
SAE collection will only be implemented following a protocol amendment.  
Timing of Recording and Reporting of SAEs 
Serious Adverse Events (SAEs) will be recorded a nd reported from the start of the Minocin IV 
infusion until [ADDRESS_1164181].  
Severity of Event:   
SAEs will be assessed by a licensed  study physician listed on the Form FDA1572 as the site 
principal investigator [INVESTIGATOR_29353]-investigator. The following guidelines will be used to 
quantify intensity.  
Mild:     Events require minimal or no treatment and do not interfere with the subject’s 
daily activities.  
Moderate:   Events result in a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with fu nctioning. 
Severe:   Events interrupt a subject’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually incapacitating.  
Changes in the severity of an AE should be documented to allow an assessment of the duration 
of the event at each level of intensity to be performed.  Adverse events characterized as intermittent require documentation of onset and duration of each epi[INVESTIGATOR_1865]. 
 
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
41 Relationship to Study Products:   
The clinician’s assessment of an SAE's relationsh ip to study drug is part of the documentation 
process, but it is not a factor in determining what is or is not reported in the study.  If there is any 
doubt as to whether a clinical observation is an SAE, the event should be reported.  All S AEs 
must have their relationship to study product assessed using the terms:  related or not related.  In 
a clinical trial, the study product must always be suspect.  To help assess, the following guidelines are used. 
Related  – There is a reasonable possibility that the study product caused the adverse event. 
Reasonable possibility means that there is evidence to suggest a causal relationship between the 
study product and the adverse event. 
Not Related  – There is not  a reasonable possibility that the administration of the study product 
caused the event.  
9.2.[ADDRESS_1164182] be submitted immediately 
(within 24  hours of site awareness) on an SAE form to the DMID Pharmacovigilance 
Group, at the following address:  
DMID Pharmacovigilance Group 
Clinical Research Operations and Management Support (CROMS)  
[ADDRESS_1164183]. Suite 650 
Bethesda, MD [ZIP_CODE], [LOCATION_003] 
SAE Hot Line: 1 -[PHONE_889] (US) or [PHONE_2619] (outside US) 
SAE FAX Phone Number: 1 -[PHONE_1729] (US) or [PHONE_2621] (outside US) 
SAE Email Address: [EMAIL_1393]  
Other supporting documentation of the event may be requested by [CONTACT_295051].  
ACUMIN   Version 3.[ADDRESS_1164184] a causal relationship between the drug and the adverse event.  DMID will notify FDA and all participating investigators (i.e., all 
investigators to whom the sponsor is providing drug under its INDs or under any investigator’s 
IND) in an IND safety report of potential serious risks from clinical trials or any other source, as 
soon as possible, but in no case later than 15 calendar days after the sponsor determines that the 
information qualifies for reporting as specified in 21 CFR Part 312.32. DMID will also notify 
FDA of any unexpected fatal or life- threatening suspected adverse reaction as soon as possible 
but in no case later than 7 calendar days after the sponsor’s initial receipt of the information. Relevant follow up information to an IND safety report will be submitted as soon as the 
information is available.  Upon request from FDA, DMID will submit to FDA any additional 
data or information that the agency deems necessary, as soon as possible, but in no case later than [ADDRESS_1164185].  
All serious events designated as “not related” to study product(s), will be reported to the FDA at 
least annually in a summary format.  
9.3.[ADDRESS_1164186] should be recorded in 
the database within 5 days of site awareness, on the Pregnancy Report form.  The report will include pregnancy outcome (e.g., any premature terminations, elective or therapeutic, any spontaneous abortions or stillbirths), as well as the health status of the mother and child, 
including date of delivery and infant’s sex and weight.  Pregnancies will be followed until birth. 
If the database is locked at time of pregnancy, a supplemental report will be generated and 
completed after birth, which will be appended to the database.  Any occurring AEs or SAEs that 
occur to the mother or fetus will be recorded in the AE or SAE eCRF in the database.  
Sites are responsible for notifying their local IRBs of any pregnancies in accordance with local 
policies.   
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
43 9.4 Type and Duration of Follow -up of Subjects after Serious Adverse 
Events  
All SAEs will be followed until resolution or stabilization.  
9.5 Halting Rules  
Further enrollment will be halted for safety monitoring committee ( SMC ) 
review/recommendation if any SAE meets the S[LOCATION_003]R  criteria . 
9.6 Safety Oversight (SMC)  
Safety oversight will be conducted by a SMC which is an independent group of experts that 
monitors subject safety and advises DMID.  Members of the SMC will be separate and independent of study personnel participating in this study and should not have scientific, 
financial or other conflict of interest related to the study.  The SMC will consist of at leas t [ADDRESS_1164187] the ad- hoc review of safety events by a local 
independent assessor at the clinical site  
The SMC meetings for  data review are as follows:  
Organizational meeting (prior to start of the study)  
Data Review Meetings (DRM) will be held during the study:  
An ad hoc SMC meeting will be convened when a halting rule is met, or at the request of the investigator and/or DMI D if there are safety concerns during the course of the study.  
Annually for aggregate review of SAEs. 
Final Data Review Meeting: [ADDRESS_1164188] summary format.  
The SMC will operate under the rules of a DMID -approved charter. Data reviews may include 
enrollment and demographic information, medical history, concomitant medications, physical 
assessments, dosing compliance, protocol a dherence, clinical laboratory values, PK data, and 
SAEs. Additional data may be requested by [CONTACT_4484], and interim statistical reports may be 
generated as deemed necessary and appropriate by [CONTACT_122830]. The SMC will receive data in aggregate. The objective of the SMC is to make recommendations to the sponsors if the study 
should continue per protocol, be modified and then proceed, or be terminated.  After each 
review/meeting the SMC will make recommendations as to the advisability of proceeding with study (as applicable), and to continue, modify, or terminate this trial. 
The DMID Medical Monitor is empowered to stop study enrollment and administration if the 
halting criteria is met or if any serious safety concerns arise.   
ACUMIN   Version 3.[ADDRESS_1164189] charts to be reviewed, which/what 
proportion of data fields and what will be monitored, and who will be responsible for conducting the monitoring visits . 
The sponsor has ethical, legal and scientific obligations to carefully follow this study in 
accordance with established research principles and applicable regulations.  The investigator, as 
part of his responsibilities, is expected to cooperate with the Sponsor in ensuring that the study adheres to the protocol and GCP requirements.   
As part of a concerted effort to fulfill these obligations, the sponsor's monitor (or designee) will 
visit the center(s) during the study in accordance with the Monitoring Plan set forth for this trial.  The investigator will permit the Spo nsor to monitor the study as frequently as is deemed 
necessary and provide access to medical records/source documents to ensure that data are being 
recorded adequately, that data are verifiable and that protocol adherence is satisfactory.   
 
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
45 11 STATISTICAL CO NSIDERATIONS 
Detailed methodology for summary and statistical analyses of the data collected in this trial will 
be documented in a Statistical Analysis Plan (SAP). This document may modify the plans 
outlined in the protocol; however, any major modifications of the primary endpoints definition and/or its analysis will also be reflected in a protocol amendment. Additional statistical analyses other than those described in this section may be performed if deemed appropriate and included 
in the plan.  
This is a n observational, single-arm, single- dose, open-label study of the pharmacokinetics and 
pharmacodynamics of Minocin IV in up to [ADDRESS_1164190] PK samples collected at designated time points over a ~[ADDRESS_1164191] ion and process ing details, please refer to the Manual of Procedures.  
11.1 Study Hypotheses  
The aim of the study is to characterize the PK of minocycline, administered as a single dose of 
Minocin IV, in critically ill subjects.  As such, no formal hypothesis testing will be performed.  The final population PK model will generate a population mean for each PK parameter; 
statistical inference will consist of associated 95% confidence intervals (CIs) around the 
parameter estimates, including estimates of the effects of patient -level and clinical covariates.   
The final population PK model will also be used to generate individual patient- specific PK 
parameters (CL, Vc, CLd and Vp) which will be used to calculate C
max, AUC 0-24, AUC 0-last, and 
AUC 0-inf.and C 24.  
To assess the probability of attaining PK- PD targets associated with microbiologic efficacy 
(achievement of fAUC:MIC targets associated with bacterial stasis and 1 -log kill for A. 
baumannii ) , Monte Carlo simulations will be conducted.  Simulations may also be used to 
assess the probability of target attainment for specific subgroups of patients and for alternate dosing strategies.  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
46 11.2 Sample Size Considerations  
The sample size for this study was selected in accordance with current guidance for PK studies.11  
11.3 Planned Interim Analyses  
No interim analyses are planned.  A safety summary report will be generated for SMC review if 
the halting rule (see Section 9.5) is met.  
11.3.1 Safety Review  
If the halting rule (see Section 9.5) is met, a safety summary report (SSR) will be produced and 
sent to the SMC.  The content and format of the SSR will be defined in the SMC charter.  
11.[ADDRESS_1164192] model the population profile. 
Non-compartmental pharmacokinetic analysis.  Non -compartmental analysis (NCA) will 
serve as the initial approach to generate base PK parameter estimates for both the free and total 
minocycline concentration -time data. An appropriate statistical analysis software package such 
as R will be used to execute the NCA.  This descriptive analysis will permit direct comparisons of 
the PK data generated from the present study to those generated th rough studies conducted 
several decades ago.   The following PK parameters will be calculated: maximum plasma 
concentration (C max), plasma concentration at 24 hours after a dose (C 24), time to  Cmax (Tmax), 
area under the curve from time zero to 12 hours (AUC 0–12), 24 hours (AUC 0–24), the last 
quantifiable sample (AUC 0–last) and infinity (AUC 0–∞). Actual infusion and sampling times will 
be used in the calculation of the PK parameters.    
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
47 Population Pharmacokinetic Analysis. Population pharmacokinetic analysis provides a 
platform to identify patient covariates which can help explain a portion of the interindividual 
variability in selected PK parameters. The non- linear mixed effects modeling software 
NONMEM Version 7.3 (ICON Development Solutions, Ellicott City, MD) will be used to 
develop the population PK model for both free and total minocycline concentrations in plasma. The first -order conditional estimation method with interaction (FOCEI) will be utilized; other 
estimation methods such as expectation -maximiza tion (e.g., SAEM) will also be considered. 
The initial approach for development of a base structural model will be to co-model the free and total plasma minocycline concentration -time data, assuming both can be adequately 
characterized using a linear two -compartment model with zero -order infusion as has been used 
previously.
[ADDRESS_1164193] selection (α=0.01) followed by [CONTACT_838122] (α=0.001) processes.  
Monte Carlo Simulation 
Using the final population PK model including all statistically significant covariate effects, 
Monte Carlo simulation will be performed to generate plasma minocycline concentration time data in a virtual population of critically ill patients with gram negative infections. Minocycline 
doses of 200 mg given as a 1-hour IV infusion, will be evaluated. The total drug and free- drug 
area under the plasma mi nocycline concentration- time curve values will then be calculated for 
each simulated patient using numerical integration. As a quality -control check, the simulated 
median and 90% prediction interval will be overlaid upon the observed plasma minocycline concentration -time data from critically -ill patients in this study where applicable to ensure the 
simulated data agree with the observed data.   
Pharmacokinetic -Pharmacodynamic Target Attainment Assessment  
The PK -PD index associated with the antimicrobial eff icacy of minocycline and other 
tetracy clines against A. baumannii  is known to be free- drug AUC:MIC ratio ( fAUC:MIC). The 
minocycline fAUC:MIC ratios which resulted in bacterial stasis and 1 -log change in log
10CFU 
was on average approximately 12 and 18 across four different clinical isolates of A. baumannii  
studied in a rat lung pneumonia infection model.13 
The percent of simulated patients achieving the fAUC:MIC target of either 12 or 18 will 
minimally be evalu ated for the FDA approved IV minocycline dosing regimen  of 200 mg 
simulated and assessed over a range of MIC values for A. baumannii. Recent surveillance MIC 
data will be obtained to assess whether the PK- PD target attainment is adequate for the majority 
of the observed MIC distribution for A. baumannii.  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
48 12 SOURCE DOCUMENTS AND  ACCESS TO SOURCE 
DATA/DOCUMENTS 
Each participating site will maintain appropriate medical and research records for this trial, in 
compliance with ICH E6, Section 4.9 and regulatory and institutional requirements for the protection of confidentiality of subjects.  Each site will permit authorized representatives of the 
DMID, its designees, and appropriate regulatory agencies to examine (and when required by 
[CONTACT_1289], to copy) clini cal records for the purposes of quality assurance reviews, audits, 
and evaluation of the study safety and progress.  These representatives will be permitted access to all source data, which include, but are not limited to, hospi[INVESTIGATOR_1097], clinical and of fice 
charts, laboratory notes, memoranda, evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_10379], microfiches, photographic negative s, microfilm or magnetic media, 
x-rays, and subject files and records kept at the pharmacy, at the laboratories, and medico-technical departments involved in the clinical trial.  Data collection forms will be derived from the eCRFs and be provided by [CONTACT_941] S tatistical and Data Coordinating Center (SDCC).  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
49 13 QUALITY CONTROL AND QUALITY ASSURANCE  
Following a written DMID -accepted protocol- specific quality management plan, each 
participating site is responsible for conducting routine quality assurance (QA) and quality control 
(QC) activities to internally monitor study progress and protocol compliance. Each  site principal 
investigator [INVESTIGATOR_92200]- related source data/data collection forms, 
reports and training documentation for the purpose of monitoring and auditing by [CONTACT_456], 
and inspection by [CONTACT_3482]. The site principal investigator [INVESTIGATOR_838106].  
The SDCC will implement quality control procedures beginning with the data entry system and 
generate data quality control checks that will be run on the database. Any missing data or data 
anomalies will be communicated to the site(s) for clarification and resolution.  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
50 14 ETHICS/PROTECTION OF  HUMAN SUBJECTS  
14.[ADDRESS_1164194]  
The investigator will ensure that this study is conducted in full conformity with the principles set 
forth in The Belmont Report: Ethical Principles and Guidelines for the Protection of Human 
Subjects of Research of the US National Commission for the Protection of Human Subjects of 
Biomedical and Behavioral Research (April 18, 1979) and codified in 45 CFR Part 46 and/or the ICH E6; 62 Federal Regulations [ZIP_CODE] (1997).   
14.[ADDRESS_1164195]  
Prior to enrollment of subjects into this trial, the approved protocol and informed consent form will be reviewed and approved by [CONTACT_838123] 
(FWA ). The responsible official for the IRB will sign the IRB letter of approval of the protocol 
prior to the start of this trial and a copy will be provided to DMID. The IRB FWA number will 
be provided to DMID. 
Should amendments to the protocol be required, the amendments will be approved by [CONTACT_838124] [INVESTIGATOR_71467]. 
14.3 Informed Consent Process  
Informed consent is a process that is initiated prior to the individual’s agreeing to part icipate in 
the study and continuing throughout the individual’s study participation.  Extensive discussion of 
risks and possible benefits of this therapy will be provided to the subject/LAR.  Consent forms 
describing in detail the study interventions/products, study procedures, and risks are given to the subject/LAR and written documentation of informed consent is required prior to starting intervention/administering study product.  Consent forms will be IRB-approved and the 
subject/LAR will be asked to rea d and review the document. Upon reviewing the document, the 
investigator will explain the research study to the subject/LAR and answer any questions that 
may arise.  The subject/LAR will sign the informed consent document prior to any procedures being done specifically for the study.  The subject/LAR should have the opportunity to discuss 
the study with their surrogates or think about it prior to agreeing to participate.  The subject/LAR 
may withdraw consent at any time throughout the course of the trial.  A copy of the informed consent document will be given to the subject/LAR for their records.  The rights and welfare of 
the subjects will be protected by [CONTACT_838125].  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
51 14.4 Exclusion of Women, Minorities, and Children (Special Populations)  
This study will enroll individuals who are receiving care in an ICU. The target population will be 
adults including all minorities. This is the first time this product is being tested in this critically ill population, and as such, pregnant women and children will not be able to be included. 
14.[ADDRESS_1164196] by [CONTACT_3486], their staff, and the sponsor(s) and their 
agents.  This confidentiality is extended to cover testing of biological samples and the clinical 
information relating to participating subjects.  
The study protocol, documentation, data, and all other information generated will be held in 
strict confidence.  No information concerning the study or the data will be released to any 
unauthorized third party without prior written approval of the sponsor. 
All info rmation provided by [CONTACT_838126] (other than a subject’s medical records) will be kept 
confidential by [CONTACT_16541] [INVESTIGATOR_838107] e xtent permitted by 
[CONTACT_2371]. This information and data will not be used by [CONTACT_16541] [INVESTIGATOR_838108]. These restrictions do not apply to: (1) 
information which becomes publicly available through no fault of the site principal investigator 
[INVESTIGATOR_29355]; (2) information which is necessary to disclose in confidence to an IRB solely for the evaluation of this trial (3) information which is necessary to disclose in order to provide appropriate medical care to a study subject; or (4) study results which may be published 
as described in Section 16. If a written contract for the conduct of this trial which includes 
confidentiality provisions inconsistent with this statement is executed, that contract’s 
confidentiality provisions shall apply rather than this statement. 
The study monitor or other authorized representatives of the sponsor may inspect all documents 
and records required to be maintained by [CONTACT_093], including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the subjects in this study.  The clinical study site will permit access to  such records.  
14.[ADDRESS_1164197] enrolled i n the study.  All source documents should be 
completed in a neat, legible manner to ensure accurate interpretation of data.  Permanent ink is required to ensure clarity of reproduced copi[INVESTIGATOR_014].  When making a change or correction, the 
original entry should be crossed out with a single line, and the change should be initialed and 
dated.  Do not erase, overwrite, or use correction fluid or tape on the original.  
Data reported in the eCRF should be consistent with the data collection form/source documents 
or the discrepancies should be documented.   
15.[ADDRESS_1164198] maintain complete and accurate documentation for the study. 
The Emmes  Corporation will serve as the Statistical and Data Coordinating Center for this study 
and will be responsible for data management, quality review, analysis, and reporting of the study 
data.  
15.2 Data Capture Methods 
Clinical data (including SAEs and concomitant medications data) and clinical laboratory data 
will be entered into a 21 CFR Part 11- compliant Internet Data Entry  System (IDES) provided by 
[CONTACT_140171].  The data system includes password protection and internal quality checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate.  Clinical data will be entered directly from the data collection forms completed by [CONTACT_197121].  
15.3 Types of Data  
Data for this study will include safety and laboratory (pharmacokinetic) data. 
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
53 15.4 Timing/Reports  
A final report will be prepared following the availability of all the c linical, safety, and 
pharmacokinetic data. Safety data will be provided to the SMC and investigators as per the SMC 
charter.  
15.[ADDRESS_1164199].  These documents should be retained for a longer period, however, if required by [CONTACT_427].  No records will be destroyed without 
the written consent of the sponsor, if applicable.  It is the responsibility of the sponsor to inform 
the investigator when these documents no longer need to be retained . 
15.6 Protocol Deviations 
A protocol deviation is any noncompliance with the clinical trial protocol, Good Clinical Practice (GCP), or Manual of Procedures requirements.  The noncompliance may be either on the part of the subject, the investigator, or the study site staff.  As a result of deviations, corrective actions 
are to be developed by [CONTACT_3483].  
These practices are consistent with ICH E6:  
4.[ADDRESS_1164200] be promptly reported to DMID, via 
The Emmes Corporation’s IDES.  
All deviations from the protocol must be addressed in study subject source documents.  A 
completed copy of the DMID Protocol Deviation Form ( IDES form) must be maintained in the 
regulatory file, as well as in the subject’s source document.  Protocol deviations must be sent to 
the local IRB per their guidelines.  The site PI/study staff is re sponsible for knowing and 
adhering to their IRB requirements.  
ACUMIN   Version 3.[ADDRESS_1164201] 
submitted them to the National Library of Medicine’s PubMed Central an electronic version of 
their final, peer-reviewed manuscripts upon acceptance for publication, to be made publically available no later than [ADDRESS_1164202] be accessible to the public on PubMed Central no later than 12 
months after publication. 
The International Committee
 of Medical Journal Editors (ICMJE) member journals have adopted 
a trials -registration policy as a condition for publication. This policy requires that all clinical 
trials be registered in a public trials registry such as ClinicalTrials.gov*, which is sponsored by 
[CONTACT_1055].  Other biomedical journals are considering adopting similar policies.  It is the responsibility of DMID to register this trial in an acceptable registry.  Any clinical trial starting enrollment after [ADDRESS_1164203] relationship between 
a medical intervention and a health outcome.  While studies designed for other purposes, such as 
to study pharmacokinetics or major toxicity (e.g., Phase I trials), are exempt from this policy, a 
separate NIH policy requires the registration and reporting in ClinicalTrials.gov for all trials 
receiving NIH funding for studies starting as of January 18, 2017. 
All publications resulting from this study will be reviewed by [CONTACT_838127].  All presentations, abstracts, or manuscripts will be reviewed by [CONTACT_838128]. 
NIH contract support will be acknowledged in all publications. 
*Journal Citation:  
De Angelis C , Drazen JM, Frizelle FA , Haug C , Hoey J , Horton R , et al. Clinical trial registration: a statement from 
the International Committee of Medical Journal Editors. N Engl J Med. 2004;351:[ADDRESS_1164204] clinical 
isolates of multidrug -resistant Acinetobacter baumannii: Clin Microbiol Infect. 2015 
Nov;21(11):e79-80. doi: 10.1016/j.cmi.2015.07.007. Epub 2015 Jul 18. 
2. Goff DA, Kaye KS. Minocycline: an old drug for a new bug: multidrug- resistant 
Acinetobacter baumannii. Clin Infect Dis 2014;1. 
3. Ritchie DJ, Garavaglia -Wilson A. A review of intravenous minocycline for treatment of 
multidrug -resistant Acinetob acter infections. Clin Infect Dis 2014;1. 
4. Chmielarczyk A, Pi[INVESTIGATOR_838109] -Zurek M, Kaminska W, et al. Molecular Epi[INVESTIGATOR_838110]: ICU as a 
Risk Factor for XDR Strains. Microb Drug Resist 2016;8:8. 
5. Gao F, Ye Q, Wan Q, Liu S, Zhou J. Distribution and resistance of pathogens in liver 
transplant recipi[INVESTIGATOR_838111]. Ther Clin Risk Manag 2015;11:501-5. 
6. Kempf M, Rolain JM. Emergence of resis tance to carbapenems in Acinetobacter baumannii 
in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents 2012;39:105-14. 
7. Nie XM, Huang PH, Ye QF, Wan QQ. The Distribution, Drug Resistance, and Clinical 
Characteristics of Acinetobacter  baumannii Infections in Solid Organ Transplant Recipi[INVESTIGATOR_840]. 
Transplant Proc 2015;47:2860-4. 
8. Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem- resistant and 
extensively drug -resistant Acinetobacter baumannii infections. Drugs 2014;74:1315-33. 
9. Shields RK, Clancy CJ, Gillis LM, et al. Epi[INVESTIGATOR_623], clinical characteristics and 
outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ 
transplant recipi[INVESTIGATOR_840]. PLoS ONE 2012;7:20. 
10. MedCo. Investigator Brochure - Minocin (minocycline) for Injection. In: Company TM, ed. 
Parsippany, NJ; 2016. 
11. Julious SA, Owen RJ. A comparison of methods for sample size estimation for non-
inferiority studies with binary outcomes. Stat Methods Med Res 2011;20:595-612. 
 
 
ACUMIN   Version 3.[ADDRESS_1164205] EMENTS/APPENDICES  
 
 
   
ACUMIN                  Version 3.0  
     19 November 2018  
57 
 APPENDIX A: SCHEDULE  OF EVENTS  
Table 1: Schedule of Events  
 
 
 
  
 
   
 
  
 
   
 
  
Screening1 Baseline  
(Hr. 0)  
 
 Study Visits (post start of infusion) 17 Supplemental 
Visit  (as 
needed )18 
 
 1 hr. 4 hrs.  12 hrs.  24 hrs.  36 hrs.  48 hrs.  
Study windows  - -30 min  +0.5 hr.  +1 hr.  ± 2 hrs.  ± 2 hrs.  ± 2 hrs.  ± 2 hrs.  - 
Clinical Evaluations  
Informed consent  
 X         
Medical History & Demographics  X         
Height 2 X1         
Weight 2  X16    X  X  
Inclusion / Exclusion Criteria  X         
Targeted Physical Examination 3 X        X 
Vital signs 4  X X16 X   X  X X 
Collection of RRT’s being received    X X X X X X  
Concomitant Medications [ADDRESS_1164206] 11 5 mL1         
Urinalysis 12 X1         
PK Blood Collection  13  6 mL15 6 mL 6 mL 6 mL 6 mL 6 mL 6 mL  
Study Drug  
Study Drug Administration   X        
APPROXIMATE TOTAL BLOOD 
  12 mL 13 mL 11 mL 11 mL 11 mL 13 mL 11 mL 13 mL  
ACUMIN                  Version 3.0  
     19 November 2018  
58 
  
 
Footnotes 
1. Screening evaluations should be completed within 48 hours prior to enrollment , with exception to  the following procedures:  
- Height can be pulled from the medical records associated with the current hospi[INVESTIGATOR_838112].  
- Clinical laboratory evaluations  obtained for clinical care purposes (standard of care results) within 48hrs of screening are acceptable for screening. A pregnancy test 
at any time during the current hospi[INVESTIGATOR_838104].  
2. Height  and weight  will be measured or calculated as per instructions in the Manual of Procedures, rather than estimated or by [CONTACT_838121].   
3. A tar geted physical examination should include an examination of specific systems, to be guided by [CONTACT_838120].  
4. Vital signs should include systolic  and diastolic blood pressure (mm Hg), heart rate (HR), respi[INVESTIGATOR_697], and temperature.  
5. Concomitant medications should be collected from [ADDRESS_1164207]  start of  infusion.  
7. Blood chemistry panel should include: potassium, sodium, chloride, bicarbonat e, glucose, blood urea nitrogen.   
8. Liver function tests should include: AST, ALT, alkaline phosphatase, albumin, total bilirubin.  
9. Serum creatinine may be run as part of the blood chemistry panel if preferred.  
10. Hematology should include: hemoglobin, hematocrit, white blood cell count [WBC], WBC differential, red blood cell count, platelets.  
11. Serum hCG pregnancy test is only required for females of child- bearing potential. 
12. Urinalysis should include: p rotein, glucose, ketones, bilirubin, blood, nitrites, LCE, urobilinogen, specific gravity, and pH . 
13. Refer to the Manual  of Procedures  for further details.  
14. A hematology panel, c hemistry panel and liver function tests should be repeated if not collected withi n [ADDRESS_1164208] art of study drug infusion  as possible.  
17. Study windows are as described in the table.  For example: 1hr time point with a window of +0.[ADDRESS_1164209] start of 
infusion.  At the 24 hour time point, the window is ± [ADDRESS_1164210] start of infusion.  
ACUMIN                  Version 3.0  
     19 November 2018  
59 
 18. Supplemental  visits should be conducted at the Investigator’s discretion and include  follow up on any SAEs that are considered related to Study Drug, as well as 
unscheduled visits . Please see protocol  Section 7.6 for details on the SAE Follow -up V isit procedures  and Section 7.8 for details on Unscheduled V isits.  
19. SAEs follow -up only after 24 hours  